Last reviewed · How we verify

Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy.

NCT01666236 Phase 4 WITHDRAWN

Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline. Treatment under study is a triple therapy with: 1) reduced-fluence photodynamic therapy (PDT), 2) intravitreal (IVT) triamcinolone and, 3) IVT ranibizumab, for the treatment of detachment of the retinal pigment epithelium (PED) secondary to Polypoidal Choroidal Vasculopathy (PCV).

Details

Lead sponsorFederal University of São Paulo
PhasePhase 4
StatusWITHDRAWN
Start date2012-09
Completion2014-09

Conditions

Interventions

Primary outcomes

Countries

Brazil